Retina/Vitreous News

The FDA granted rare pediatric disease and fast track designations to gildeuretinol, an investigational oral therapy for the treatment of Stargardt disease, according to a press release from Alkeus Pharmaceuticals.

The European Commission has approved Opuviz 40 mg/mL solution, a biosimilar referencing Eylea, according to a press release from Samsung Bioepis and Biogen.

Adverum Biotechnologies reported positive 52-week data from the phase 2 LUNA trial as well as long-term follow-up results from the OPTIC trial of Ixo-vec in patients with wet age-related macular degeneration.

Evaluations of diabetic retinopathy severity appeared comparable with ultra-widefield and 7-field imaging, suggesting ultra-widefield imaging can be used in future longitudinal studies without bias, according to a cross-sectional study.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Matteo Forlini, MD, discusses a Vit-Buckle Society session on surgical challenges.

NEW YORK — In this Healio Video Perspective from OSN New York Retina, Rishi P. Singh, MD, FASRS, of Cleveland Clinic Florida discusses the need for anti-VEGF biosimilars and the possibility of on-label bevacizumab.

A decrease in the number of orbital decompression surgeries in patients with thyroid eye disease may be attributed to the introduction of teprotumumab treatment, according to a study published in Canadian Journal of Ophthalmology.

Although best corrected visual acuity was the only visual function test ready for immediate use in a diabetic retinal disease staging system, others showed promise or potential, according to a report published in Ophthalmology Science.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Paulo-Eduardo Stanga, MD, speaks in favor of treating vitreous floaters and opacities.